Table 1. Patients' pretreatment characteristics.
| Characteristic (n=28) | n (%) |
| Gender | |
| Male | 17 (61) |
| Female | 11 (39) |
| Age | |
| Median | 55 |
| Range | 29–70 |
| ECOG performance status | |
| 0 | 3 (11) |
| 1 | 21 (75) |
| 2 | 4 (14) |
| Histology | |
| GBM | 16 (57) |
| Anaplastic oligodendroglioma | 3 (11) |
| Anaplastic astrocytoma | 9 (32) |
| Previous treatments | |
| Surgery/biopsy | 28 (100) |
| Radiotherapy | 27 (96) |
| Chemotherapy | 26 (93) |
| Antiepileptic drugs | |
| None | 4 (14) |
| EIAEDs | 21 (75) |
| Non-EIAEDs | 3 (11) |
ECOG=Eastern Cooperative Oncology Group; EIAEDs=enzyme-inducing antiepileptic drugs; GBM=glioblastoma.